ギラン・バレー症候群の病態解明と治療法選択(<特集>免疫性神経疾患とアフェレシス,新しい展望)

概要

論文の詳細を見る
Guillain-Barre syndrome (GBS), a post-infectious autoimmune neuropathy, manifests an acute onset and a monophasic course, suggesting that early aggressive treatment is needed. Presently, due to its wide availability, ease of administration, and favorable side-effect profile, intravenous immunoglobulin is considered to be the first-line treatment for patients with GBS. Plasma exchange is also effective for GBS and its therapeutic effect seems to be related to the removal of circulating IgG autoantibodies. Ganglioside epitopes on Campylobacter jejuni, the leading antecedent pathogen, are hypothesized as the key to the production of anti-ganglioside IgG autoantibodies, resulting in the development of GBS. The genetic polymorphism of C. jejuni determines autoantibody reactivity and the clinical presentation of GBS, possibly through modification of the host-mimicking molecule. Experimental studies demonstrated the pathogenic role of anti-ganglioside IgG antibodies, indicating a possible approach to autoantigen-specific immunoadsorption treatment in GBS.
日本アフェレシス学会の論文
2004-10-31